Charlestrad3r

Unusual Volume, rich catalyst program in 2020

Long
AMEX:AIM   AIM ImmunoTech Inc.
AIM
Has a Gap to fill & seen big unsual buying. Has a very Low float.

A Biotech stock targeting diffrent cancers, a lot of data due throughout 2020
- Triple-Negative Breast Cancer ; Phase 1 data due 2Q
- Colorectal cancer ; Phase 2 date due 2Q
- Ovarian cancer ; Phase 1 interim data due 1Q
- Ovarian cancer ; Phase 2 data due 4Q

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.